Ocular Therapeutix announces positive Phase 2 PAXTRAVA™ glaucoma data, showing sustained IOP reductions with a single implant for six months.
Ocular Therapeutix announces positive Phase 2 PAXTRAVA™ glaucoma data, showing consistent and sustained IOP reductions (p<0 .0001) a for implant.< months single six span with> Results indicate 24-30% reductions and good tolerance with no corneal health impact. The study suggests potential for repeat dosing without implant stacking, and the company plans to expand its focus on retinal diseases. April 06, 20245 Articles